| P50 | author | Alastair Forbes | Q58459763 |
| P2093 | author name string | S Schreiber | |
| | S Ghosh | |
| | I D R Arnott | |
| | C S J Probert | |
| | S D Hearing | |
| | T Kühbacher | |
| P2860 | cites work | Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent | Q28191546 |
| | EuroQol--a new facility for the measurement of health-related quality of life | Q29547873 |
| | Treatment of ulcerative colitis in the cottontop tamarin using antibody to tumour necrosis factor alpha | Q33618096 |
| | Infliximab for the treatment of fistulas in patients with Crohn's disease | Q33860666 |
| | Cyclosporine in severe ulcerative colitis refractory to steroid therapy | Q34060783 |
| | Cyclosporine in ulcerative colitis: state of the art. | Q34320512 |
| | Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease | Q34377789 |
| | Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease | Q34394083 |
| | Predicting outcome in severe ulcerative colitis | Q34409849 |
| | Predicting therapeutic outcome in severe ulcerative colitis by measuring in vitro steroid sensitivity of proliferating peripheral blood lymphocytes | Q35356941 |
| | Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions | Q41355139 |
| | Audit of cyclosporin use in inflammatory bowel disease: limited benefits, numerous side-effects. | Q41750258 |
| | Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. | Q41941349 |
| | Infliximab in severe steroid-refractory ulcerative colitis: a pilot study. | Q42668130 |
| | Anti-tumour necrosis factor alpha (infliximab) in the treatment of severe ulcerative colitis: result of an open study on 13 patients. | Q42686834 |
| | Infliximab for treatment of steroid-refractory ulcerative colitis | Q42686841 |
| | Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis | Q43679139 |
| | Treatment of ulcerative colitis with an engineered human anti-TNFalpha antibody CDP571. | Q47847779 |
| | A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. | Q53964227 |
| | Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. | Q54007642 |
| | Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study | Q68206432 |
| | Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine | Q68350435 |
| | Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease | Q70489716 |
| | Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease | Q73107122 |
| | Mechanisms in failure of infliximab for Crohn's disease | Q73197599 |
| | Infliximab for refractory ulcerative colitis | Q74400737 |
| | Clinical use of Infliximab in Crohn's disease: the Edinburgh experience | Q74530732 |
| | Intravenous cyclosporin as rescue therapy in severe ulcerative colitis: time for a reappraisal? | Q74627465 |
| | VARIATION BETWEEN OBSERVERS IN DESCRIBING MUCOSAL APPEARANCES IN PROCTOCOLITIS | Q76593193 |
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ulcerative colitis | Q1477 |
| | randomized controlled trial | Q1436668 |
| P304 | page(s) | 998-1002 | |
| P577 | publication date | 2003-07-01 | |
| P1433 | published in | Gut | Q5621669 |
| P1476 | title | Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial | |
| P478 | volume | 52 | |